Spinocerebellar degeneration

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 10, 2003, Pages 1637-1641

  Perlman, Susan L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Animal models; Antioxidants; Biomarkers; Rating scales; Spinocerebellar

Indexed keywords

3,4 DIAMINOPYRIDINE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; ACETAZOLAMIDE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMANTADINE; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BIOLOGICAL MARKER; BUSPIRONE; CARBONATE DEHYDRATASE INHIBITOR; CARNITINE; CLONAZEPAM; CREATININE; GABAPENTIN; ICOSAPENTAENOIC ACID ETHYL ESTER; IDEBENONE; NEUROTRANSMITTER; POTASSIUM CHANNEL BLOCKING AGENT; PROTIRELIN; RIBOFLAVIN; SCAVENGER; SELENIUM; SEROTONIN 1A AGONIST; SOMATOMEDIN C; TALTIRELIN; THIOCTIC ACID; UBIDECARENONE; UNINDEXED DRUG;

ANIMAL MODEL; CEREBELLAR ATAXIA; CEREBELLUM; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG LABELING; DRUG USE; EDITORIAL; FOOD AND DRUG ADMINISTRATION; FRIEDREICH ATAXIA; HUMAN; INHERITANCE; MENTAL DETERIORATION; NEUROLOGIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; RATING SCALE; REHABILITATION; RELIABILITY; SPINOCEREBELLAR DEGENERATION; SYMPTOMATOLOGY; VALIDATION PROCESS;

ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; FREE RADICAL SCAVENGERS; GABA AGONISTS; GENE THERAPY; HUMANS; RECEPTORS, N-METHYL-D-ASPARTATE; SPINOCEREBELLAR DEGENERATIONS;

EID: 0142179179     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.10.1637     Document Type: Editorial

References (58)

1. PERLMAN SL: Cerebellar Ataxia. Curr. Treat. Options Neurol. (2000) 2:215-224.
2. GOMEZ C: Inherited cerebellar ataxias. In: Current Therapy in Neurological Disease. Johnson RT, Griffin JW, McArthur JC (Eds), Mosby, St. Louis, USA (2001).
3. PERLMAN SL: Diagnostic evaluation of ataxic patients. In: Genetics of Movement Disorders. Pulst SM (Ed.), Academic Press, San Diego, USA (2003).
4. LYNCH DR, FARMER JM, BALCER LJ, WILSON RB: Friedreich ataxia: effects of generic understanding on clinical evaluation and therapy. Arch. Neurol. (2002) 59:743-747.
5. TAYLOR JP, HARDY J, FISCHBECK KH: Toxic proteins in neurodegenerative disease. Science (2002) 296:1991-1995.
6. RANUM LP, DAY JW: Dominantly inherited, non-coding microsatellite expansion disorders. Curr. Opin. Genet. Dev. (2002) 12:266-271.
7. BURRIGHT EN, CLARK HB, SERVADIO A et al.: SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell (1995) 82:937-948.
8. HUYNH DP, FIGUEROA K, HOANG N, PULST SM: Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat. Genet. (2000) 26:44-50.
9. CEMAL CK, CARROLL CJ, LAWRENCE L et al.: YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum. Mol. Genet. (2002) 11:1075-1094.
10. YVERT G, LINDENBERG KS, PICAUD S, LANDWEHRMEYER GB, SAHEL JA, MANDEL JL: Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. Hum. Mol. Genet. (2000) 9:2491-2506.
11. SATO T, OYAKE M, NAKAMURA K et al.: Transgenic mice harboring a full-length human mutant DRPLA gene exhibit age-dependent intergenerational and somatic instabilities of CAG repeats comparable with those in DRPLA patients. Hum. Mol. Genet. (1999) 8:99-106.
12. MIRANDA CJ, SANTOS MM, OHSHIMA K et al.: Frataxin knockin mouse. FEBS Lett. (2002) 512:291-297.
13. TORRES-ALEMAN I, BARRIOS V, LLEDO A, BERCIANO J: The insulin-like growth Factor I system in cerebellar degeneration. Ann. Neurol. (1996) 39:335-342.
14. PIEMONTE F, PASTORE A, TOZZI G et al.: Glutathione in blood of patients with Friedreich's ataxia. Eur. J. Clin. Invest. (2001) 31:1007-1011.
15. SCHULZ JB, DEHMER T, SCHOLS L et al.: Oxidative stress in patients with Friedreich ataxia. Neurology (2000) 55:1719-1721.
16. TROUILLAS P, TAKAYANAGI T, HALLETT M et al.: International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J. Neurol. Sci. (1997) 145:205-211.
17. LYNCH DR, FARMER JM, WILSON RB, BALCER LJ: Clinical measures in Friedreich ataxia. Neurology (2003) 60:A271.
18. CRAWFORD TO, MANDIR AS, LEFTON-GREIF MA et al.: Quantitative neurological assessment of ataxia-telangiectasia. Neurology (2000) 54:1505-1509.
19. OERTEL WH: Neurotransmitters in the cerebellum. Scientific aspects and clinical relevance. In: Inherited Ataxias. Harding AE, Deufel T (Eds), Raven Press, New York, USA (1993).
20. GAZULLA JE JM, BENAVENTE I, TORDESILLAS C: Improvement of ataxic signs in cortical cerebellar atrophy with the GABAergic drug gabapentin. Neurology (2003) 60:A472.
21. WARAGAI M, OGAWARA K, TAKAYA Y, HAYASHI M: [Efficacy of TRH-T for spinocerebellar degeneration - the relation between clinical features and effect of TRH therapy]. Rinsho Shinkeigaku (1997) 37:587-594.
22. LAMBERT D, WATERS CH: Essential tremor. Curr. Treat. Options Neurol. (1999) 1:6-13.
23. AVERBUCH-HELLER L: Acquired nystagmus. Curr. Treat. Options Neurol. (1999) 1:68-73.
24. STRUPP M, SCHULER O, KRAFCZYK S et al.: Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology (2003) 61:165-170.
25. WAN J, BALOH RW, JEN JC: Mechanism of action of acetazolamide in treatment of episodic ataxia Type 2. Neurology (2003) 60:A330.
26. JEN JC, YUE Q, KARRIM J, NELSON SF, BALOH RW: Spinocerebellar ataxia Type 6 with positional vertigo and acetazolamide responsive episodic ataxia. J. Neurol. Neurosurg. Psychiatry (1998) 65:565-568.
27. YABE I, SASAKI H, YAMASHITA I, TAKEI A, TASHIRO K: Clinical trial of acetazolamide in SCA6, with assessment using the Ataxia Rating Scale and body stabilometry. Acta Neurol. Scand. (2001) 104:44-47.
28. JEN JC, BALOH RW: Genetics of episodic ataxia. Adv. Neurol. (2002) 89:459-461.
29. ZHANG W, LEE WH, TRIARHOU LC: Grafted cerebellar cells in a mouse model of hereditary ataxia express IGF-I system genes and partially restore behavioral function. Nat. Med. (1996) 2:65-71.
30. KAEMMERER WF, LOW WC: Cerebellar allografts survive and transiently alleviate ataxia in a transgenic model of spinocerebellar ataxia type-1. Exp. Neurol. (1999) 158:301-311.
31. FERNANDEZ AM, GONZALEZ DE LA VEGA AG, PLANAS B, TORRES-ALEMAN I: Neuroprotective actions of peripherally administered insulin-like growth Factor I in the injured olivo-cerebellar pathway Eur. J. Neurosci. (1999) 11:2019-2030.
32. SCHON EA, MANFREDI G: Neuronal degeneration and mitochondrial dysfunction. J. Clin. Invest. (2003) 111:303-312.
33. MATTSON MP: Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med. (2003) 3:65-94.
34. FRIEDLANDER RM: Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med. (2003) 348:1365-1375.
35. RUSTIN P: The use of antioxidants in Friedreich's ataxia treatment. Expert Opin. Investig. Drugs (2003) 12:569-275.
36. RUSTIN P, VON KLEIST-RETZOW JC, CHANTREL-GROUSSARD K, SIDI D, MUNNICH A, ROTIG A: Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet (1999) 354:477-479.
37. SCHOLS L, VORGERD M, SCHILLINGS M, SKIPKA G, ZANGE J: Idebenone in patients with Friedreich ataxia. Neurosci. Lett. (2001) 306:169-172.
38. HAUSSE AO, AGGOUN Y, BONNET D et al.: Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart (2002) 87:346-349.
39. BUYSE G, MERTENS L, DI SALVO G et al.: Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring. Neurology (2003) 60:1679-1681.
40. MARIOTTI C, SOLARI A, TORTA D, MARANO I, FIORENTINI C, DI DONATO S: Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology (2003) 60:1676-1679.
41. KELSO GF, PORTEOUS CM, HUGHES G et al.: Prevention of mitochondrial oxidative damage using targeted antioxidants. Ann. NY Acad. Sci. (2002) 959:263-274.
42. RICHARDSON DR: Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy?. Expert Opin. Investig. Drugs (2003) 12:235-245.
43. KAEMMERER WF, RODRIGUES CM, STEER CJ, LOW WC: Creatine-supplemented diet extends Purkinje cell survival in spinocerebellar ataxia Type 1 transgenic mice but does not prevent the ataxic phenotype. Neuroscience (2001) 103:713-724.
44. PEYSER CE, FOLSTEIN M, CHASE GA et al.: Trial of d-alpha-tocopherol in Huntington's disease. Am. J. Psychiatry (1995) 152:1771-1775.
45. GROUP HS: A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology (2001) 57:397-404.
46. TABRIZI SJ, BLAMIRE AM, MANNERS DN et al.: Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. Neurology (2003) 61:141-142.
47. MARCELAIN K, NAVARRETE CL, BRAVO M, SANTOS M, BE C, PINCHEIRA J: [Effect of vitamin E (DL-alpha-tocopherol) on the frequency of chromosomal damage in lymphocytes from patients with ataxia telangiectasia]. Rev. Med. Chil. (2002) 130:957-963.
48. GATEI M, SHKEDY D, KHANNA KK et al.: Ataxia-telangiectasia: chronic activation of damage-responsive functions is reduced by alpha-lipoic acid. Oncogene (2001) 20:289-294.
49. SEPPI K, MUELLER J, BODNER T et al.: Riluzole in Huntington's disease (HD): an open label study with one year follow up. J. Neurol. (2001) 248:866-869.
50. DEIGNER HP, HABERKORN U, KINSCHERF R: Apoptosis modulators in the therapy of neurodegenerative diseases. Expert Opin. Investig. Drug (2000) 9:747-764.
51. STEFFAN JS, THOMPSON LM: Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases. Expert Opin. Ther. Targets (2003) 7:201-213.
52. BONELLI RM, HEUBERGER C, REISECKER F: Minocycline for Huntington's disease: an open label study. Neurology (2003) 60:883-884.
53. SMITH DL, WOODMAN B, MAHAL A et al.: Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann. Neurol. (2003) 54:186-196.
54. CUMMINGS CJ, SUN Y, OPAL P et al.: Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum. Mol. Genet. (2001) 10:1511-1518.
55. YOSHIDA H, YOSHIZAWA T, SHIBASAKI F, SHOJI S, KANAZAWA I: Chemical chaperones reduce aggregate formation and cell death caused by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch. Neurobiol. Dis. (2002) 10:88-99.
56. STEFFAN JS, BODAI L, PALLOS J et al.: Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature (2001) 413:739-743.
57. HOCKLY E, RICHON VM, WOODMAN B et al.: Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA (2003) 100:2041-2046.
58. MILLER VM, XIA H, MARRS GL et al.: Allele-specific silencing of dominant disease genes. Proc. Natl. Acad. Sci. USA (2003) 100:7195-7200.